M&A

Fierce Pharma

Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears

With Xtandi set to lose U.S. patent protection next year, Astellas’ CEO fielded questions this week about his company’s BD strategy ahead of the loss.

Angus Liu Jan 15, 2026 10:42am

Boston Scientific to snap up Penumbra in deal valued at $14.5B

Jan 15, 2026 8:12am

JPM26: All of the meetings, none of the megadeals

Jan 15, 2026 4:30am

Fierce Pharma

JPM26: Leo Pharma sharpens its eye for dermatology dealmaking

Jan 13, 2026 2:45pm

Fierce Pharma

Bristol Myers CEO pledges to 'cast a broad net' in dealmaking

Jan 12, 2026 4:28pm

MA strategy deal block push come together form

Haemonetics to pay up to €185M to acquire device maker Vivasure

Jan 12, 2026 9:55am